Concurrent and robust regulation of feeding behaviors and metabolism by orexin neurons

Ayumu Inutsuka a, Azusa Inui a, Sawako Tabuchi a, Tomomi Tsunematsu a, Michael Lazarusb, Akihiro Yamanakac

a Department of Neuroscience II, Research Institute of Environmental Medicine, Nagoya University, Nagoya 464-8601, Japan
b International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, Tsukuba 305-8575, Japan

1. Introduction

The neuropeptide orexin (hypocretin) has been known to be involved in feeding behavior since its early identification. In 1998, two groups independently identified this neuropeptide. One group named it “hypocretin” as they had found the peptide in the hypothalamus (De Lecea et al., 1998), and the other group named it “orexin” due to its putative role as a regulator of feeding behavior (Sakurai et al., 1998). Orexin is now known to regulate not only orexin but also other neurotransmitters such as glutamate and dynorphin. In this study, we examined the physiological role of orexin neurons in feeding behavior and metabolism by pharmacogenetic activation and chronic ablation. We generated novel orexin-Cre mice and utilized Cre-dependent adeno-associated virus vectors to express Gq-coupled modified GCPR, hM3Dq or diphtheria toxin fragment A in orexin neurons. By intraperitoneal injection of clozapine-N oxide in orexin-Cre mice expressing hM3Dq in orexin neurons, we could selectively manipulate the activity of orexin neurons. Pharmacogenetic stimulation of orexin neurons simultaneously increased locomotive activity, food intake, water intake and the respiratory exchange ratio (RER). Elevation of blood glucose levels and RER persisted even after locomotion and feeding behaviors returned to basal levels. Accordantly, 83% ablation of orexin neurons resulted in decreased food and water intake, while 70% ablation had almost no effect on these parameters. Our results indicate that orexin neurons play an integral role in regulation of both feeding behavior and metabolism. This regulation is so robust that greater than 80% of orexin neurons were ablated before significant changes in feeding behavior emerged.

© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
whereas orexin neuron-ablated transgenic mice develop hypophagia and late-onset obesity in addition to narcoleptic symptoms (Hara et al., 2001). Orexin neurons express not only orexins but also dynorphin (Chou et al., 2001) and glutamate (Abrahamson et al., 2001). Therefore, these differences in phenotype might suggest the involvement of other neurotransmitters besides orexin in the regulation of feeding and energy balance. Because it is unlikely that orexin peptides are the only factors released by orexin neurons in vivo, it is worth investigating the effects of selective manipulation of orexin neurons.

In this study, we generated a new orexin-Cre mouse line and employed a pharmacogenetic technique called designer receptors exclusively activated by designer drugs (DREADD) to selectively manipulate the activity of orexin neurons in free-moving mice. This method utilizes modified GPCRs to achieve selective, rapid and reversible modulation of neuronal activity. In short, muscarinic GPCRs are mutated so that their ability to bind their original ligand, acetylcholine, is lost while the synthetic ligand clozapine-N-oxide (CNO) can activate them (Armbruster et al., 2007). Cq-coupled DREADD, hM3Dq activates neurons through phospholipase C-dependent signal transduction (Alexander et al., 2009). Compared with optogenetic techniques utilizing ion channels, activation of GPCRs has a relatively longer effect on cellular signaling. Therefore, it is reasonable to employ DREADD to modulate the activity of orexin neurons for an extended time in order to examine the effects on feeding behavior and metabolism. We also selectively ablated orexin neurons using diphtheria toxin fragment A (DTA) to investigate the physiological roles of orexin neurons in feeding behaviors and metabolism.

Our results show that selective activation of orexin neurons simultaneously affects feeding behaviors and metabolism and that only 30% of orexin neurons are required to maintain such functions. These findings demonstrate the robust and concurrent regulation of feeding behaviors and wakefulness by orexin neurons.

2. Materials and methods

2.1. Animal usage

All experimental procedures involving animals were approved by the Institutional Animal Care and Use Committee of Research Institute of Environmental Medicine, Nagoya University. Mice were maintained under a strict 12 h light: dark cycle (light period: 8:00–20:00; dark period: 20:00–8:00) in a temperature-controlled room (22 ± 1 °C). Food and water were available ad libitum except for in the experiments shown in Fig. 4. All efforts were made to minimize animal suffering and discomfort and to reduce the number of animals used.

2.2. Generation of orexin-Cre mice

The transgene was constructed with a 3.2-kb fragment of the 5′-upstream region of the human prepro-orexin gene as a promoter,Cre recombinase cDNA fused to EGFP with the 2A peptide, and the murine protamine-1 gene intron and poly(A) gion of the human prepro-orexin gene as a promoter. Cre recombinase cDNA fused with benzonase nuclease (Merck, Darmstadt, Germany) at 45 °C for 15 min, and centrifuged 2 times at 16,000 g for 10 min. The supernatant was used as the virus-containing solution. To measure the titer of purified virus dissolved in artificial CSF, quantitative PCR was performed; the virus was stored at –80 °C in aliquots before use. The pAAV-hSyn-FLEX-hM3Dq-mCherry plasmid was purchased from Addgene (ID: 44361).

2.3. Adeno-associated virus (AAV) production and purification

All AAV vectors were produced using the AAV Helper-Free System (Agilent Technologies, Inc., Santa Clara, CA, USA), and purified according to published methods (Lazarus et al., 2011). Briefly, HEK293 cells were transfected with a pAAV vector plasmid that included a gene of interest, pHelper, and pAAV-RC (serotype 10; provided by Penn Vector Core) using a standard calcium phosphate method. Three days later, the transfected cells were collected and suspended in artificial CSF (124 mM NaCl, 3 mM KCl, 26 mM NaHCO3, 2 mM CaCl2, 1 mM MgSO4, 1.25 mM KH2PO4, 10 mM Na-α-Glucose). After 4 freeze–thaw cycles, the cell lysate was treated with benzonase nuclease (Merck, Darmstadt, Germany) at 45 °C for 15 min, and centrifuged 2 times at 16,000 g for 10 min. The supernatant was used as the virus-containing solution. To measure the titer of purified virus dissolved in artificial CSF.

2.4. Stereotaxic AAV injection

Surgures for AAV injections were conducted under pentobarbital anesthesia (50 mg/kg, i.p.) using a stereotaxic instrument (David Kopf Instruments, Tujunga, CA, USA). Eight-week-old mice were injected stereotaxically into the LHA with recombinant AAV-2A-Cre cDNA, and mouse protamine intron and poly(A) signal. Viral 2A peptide is cleaved just after translation, and EGFP and Cre recombinase localize independently. B: Specific expression of EGFP and Cre recombinase in orexin neurons. Immunohistochemistry showed specific expression of EGFP or Cre recombinase in orexin neurons in the LHA. Quantitative analysis showed 91.2 ± 0.9% (n = 8) colocalization of Cre recombinase with orexin. Scale bars, 100 μm (upper row) and 50 μm (middle and lower row).

Fig. 1. Generation of orexin-Cre mice that express EGFP and Cre recombinase exclusively in orexin neurons. A: Schematic representation of the orexin-Cre transgene. To achieve orexin neuron-specific expression of Cre recombinase, we used a 3.2 kb 5′-upstream region of human prepro-orexin gene as a promoter. The transgene consists of the orexin promoter, EGFP-2A-Cre cDNA, and mouse protamine intron and poly(A) signal. Viral 2A peptide is cleaved just after translation, and EGFP and Cre recombinase localize independently. B: Specific expression of EGFP and Cre recombinase in orexin neurons. Immunohistochemistry showed specific expression of EGFP or Cre recombinase in orexin neurons in the LHA. Quantitative analysis showed 91.2 ± 0.9% (n = 8) colocalization of Cre recombinase with orexin. Scale bars, 100 μm (upper row) and 50 μm (middle and lower row).

2.5. Analysis of feeding behaviors and metabolism

Locomotion, food intake, water intake, and the RER were concurrently recorded using CLAMS. CLAMS is a set of live-in cages for automated, non-invasive, and simultaneous monitoring of horizontal and vertical activity, feeding and drinking, oxygen consumption, and CO2 production. Twelve-week-old mice were individually placed in CLAMS cages and monitored for more than 5 days. The first 3 days were used as an acclimation period. Food and water consumption were measured directly.
Membrane potential and greatly increased the orexin neuron identified by mCherry fluorescence from an orexin-Cre mouse injected with AAV-hSyn-FLEX-hM3Dq-mCherry. CNO (1.0 mg/kg, i.p.). Scale bar, 50 μm. F: Quantitative analysis of c-Fos activation of neurons at ZT13.5 in orexin-Cre mice injected with the hM3Dq AAV vector and administered saline or CNO at ZT 12 (n = 7).

2.6. Immunohistochemistry

The mice were deeply anesthetized with isoflurane and transcardially perfused with 20 ml of chilled saline, followed by 20 ml of chilled 10% formalin solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan). The brain was removed, post-fixed in 10% formalin solution at 4 °C overnight, and immersed in 30% sucrose in PBS at 4 °C for at least 2 days. A series of 40 μm sections were obtained with a cryostat (Leica CM3050 S; Leica Microsystems, Wetzlar, Germany).

For staining, coronal brain sections were immersed in blocking buffer (1% BSA and 0.25% Triton-X in PBS), then incubated with primary antibodies at 4 °C overnight. The sections were washed with blocking buffer then incubated with secondary antibodies for 1 h at RT. The brain slices were then transferred to a recording chamber (RC-27L, Warner Instruments, Hamden, CT, USA) on a microscope stage (BX51WI; Olympus, Tokyo, Japan). The infrared differential interference contrast imaging and a CCD camera (IK-TU51CU, Hamamatsu Photonics, Hamamatsu, Japan) for infrared differential interference contrast imaging and a CCD camera (IK-TU51CU, Hamamatsu, Japan). Neurons with mCherry fluorescence were categorized as orexin neurons and were subjected to electrophysiological recordings. Recordings were performed with an Axopatch 200B amplifier (Molecular Devices LLC, Sunnyvale, CA, USA) using a borosilicate pipette (CF150-10; Harvard Apparatus, Holliston, MA, USA) prepared by a micropipette puller (P-1000; Sutter Instruments, Novato, CA, USA) filled with intracellular solution (4–10 MΩ), consisting of the following (in mM): 138 K-gluconate, 8 NaCl, 10 HEPES, 0.2 EGTA-Na2, 2 MgATP, and 0.5 Na2GTP, pH 7.3 with KOH. During recordings, cells were superfused with extracellular solution at a rate of 1.6 ml/min using a peristaltic pump (Pymaxan; Rainin Instrument LLC, Oakland, CA, USA). CNO (Sigma–Aldrich) was dissolved in extracellular solution at a concentration of 30 μM and applied by local application through a fine tube (100 μm diameter) positioned near the recording neurons. The output signal was low-pass filtered at 5 kHz and digitized at 10 kHz. Data were recorded on a computer through a Digidata 1322A A/D converter using pClamp software (version 10,
Fig. 3. Transient activation of orexin neurons alters locomotion, food intake, water intake and RER. Orexin-Cre or wild type mice were injected with AAV-hSyn-FLEX-hM3Dq-mCherry in the LHA. After 4 weeks, to allow for gene expression, they were injected with CNO (1.0 mg/kg, i.p.) or saline at 12:00 (ZT4). All mice were monitored using a comprehensive laboratory animal monitoring system (CLAMS), which continuously records activity. A–C: Ambulatory locomotion activity, D–F: Food intake, G–I: Water intake, and J–L: Respiratory exchange ratio. Data measured during 10 min intervals are plotted as mean ± SEM (WT, n = 15; Tg, n = 9) in the left and middle columns. The summation (C, F and I) or average (L) of each plot during the 4 h (from ZT 4 to ZT 8) is analyzed in the right column. The data were analyzed by one-way ANOVA followed by Tukey–Kramer multiple comparison tests.

Fig. 4. Transient activation of orexin neurons alters blood glucose in fasting mice. Orexin-Cre or wild type mice were injected with AAV-hSyn-FLEX-hM3Dq-mCherry in the LHA at 8 weeks old. After 4 weeks they were injected with CNO (1.0 mg/kg, i.p.) or saline at 12:00 (ZT4); Measurements at 12:00 were done just before CNO/saline injection. All the mice were fasted from 20:00 (ZT12) on the day before the experiments. A, B: The time course of fasting blood glucose before and after i.p. injection of saline or CNO into orexin-Cre and wild type mice infected with AAV vectors. Measured data are plotted as mean ± SEM (WT, n = 15; Tg, n = 9). C: Quantitative analysis of average blood glucose during 4 h from ZT5 to ZT8. The data were analyzed by one-way ANOVA followed by Tukey–Kramer tests.
3. Results

3.1. Cre recombinase is exclusively expressed in orexin neurons in novel orexin-Cre mice

To achieve specific expression in orexin neurons, we first generated a novel orexin-Cre mouse line. The utility of the 3.2 kb fragment of the 5′-upstream region of the human prepro-orexin gene for expressing genes of interest in orexin neurons has been previously reported (Sakurai et al., 1999; Moriguchi et al., 2002; Tsunematsu et al., 2011), so we employed this sequence as a promoter (Fig. 1A). The Cre recombinase was fused to EGFP with a self-cleaving 2A peptide from the Thasea asigna virus to easily recognize orexin neurons by fluorescence without immunostaining. The viral 2A peptide is immediately cleaved upon translation, which allows expression of multiple proteins from a single ORF (Szymczak et al., 2004). The transgene was excised and microinjected into pronuclei of fertilized C57BL/6J mouse eggs to generate transgenic founders. Founders were bred with C57BL/6J mice to produce stable transgene-positive founders. Five transgene-positive founders were obtained from the orexin-Cre transgenic lines. Analysis of the N1 generation demonstrated that only two lines showed sufficient expression of Cre recombinase. The orexin-Cre transgenic line that showed the highest Cre expression in orexin neurons was used in subsequent experiments.

Histological sections were examined from regions throughout the brain of orexin-Cre mice, and EGFP-expressing cells were found exclusively in the LHA. Immunohistochemistry with anti-Cre recombinase and anti-orexin-A antibody showed 91.2 ± 0.9% (n = 8) co-localization of Cre recombinase with orexin (Fig. 1B). No ectopic expression of EGFP or Cre recombinase was observed. Note that Cre recombinase was localized to the nucleus because of its nuclear localization signal at the N-terminus, while EGFP was localized throughout the soma. This finding demonstrates their successful separation by 2A peptide cleavage.

3.2. Expression and pharmacogenetic activation of hM3Dq in orexin neurons

To selectively manipulate activity of orexin neurons, we employed designer receptors exclusively activated by designer drugs (DREADD) technology. We used a Cre-dependent adeno-associated viral vector to specifically target the stimulatory hM3Dq DREADD to orexin neurons. The hM3Dq receptor has a high affinity for the synthetic ligand CNO (Alexander et al., 2009), and CNO administration can induce depolarization and firing of hM3Dq-expressing neurons. Stable transgene inversion was achieved by employing a FLEX (flip-excision) switch. The FLEX switch consists of paired loxP and lox2272 sequences and enables the expression of a gene of interest only when Cre recombinase is present (Atasoy et al., 2008) (Fig. 2A). Fused mCherry was used to monitor the expression of hM3Dq.

AAV-hSyn-FLEX-hM3Dq-mCherry was stereotaxically injected into the LHA of eight-week-old orexin-Cre mice, and mice were sacrificed 4 weeks after injection. Immunohistochemistry showed that hM3Dq was expressed exclusively in orexin neurons (Fig. 2B). Using fused mCherry as a marker, 71.3 ± 6.8% (n = 7) of orexin neurons were shown to express hM3Dq-mCherry.

We then performed whole-cell current clamp recordings to determine the ability of hM3Dq to activate orexin neurons in vitro. Orexin-Cre mice were injected with AAV-hSyn-FLEX-hM3Dq-mCherry in the LHA at 3 weeks of age, and were sacrificed 7 weeks after injection to obtain brain slices. Neurons strongly expressing mCherry were considered to be orexin neurons and were subjected to whole-cell recordings. Local application of CNO (30 μM) to brain slices greatly increased the firing rate of orexin neurons (Fig. 2C). This CNO-induced depolarization was sustained for about 10 min after washout, and was reversible. We also confirmed that application of CNO did not affect the membrane potential of orexin neurons not expressing hM3Dq-mCherry (P < 0.01; Student’s t-test; n = 5) (Fig. 2D).

Next, we checked the neuronal activation by hM3Dq in vivo. Neuronal activity of orexin neurons changes in accordance with arousal state; c-Fos expression in orexin neurons is low during the light period and high during the dark period (Estabrooke et al., 2001). Therefore, we examined the effects of excitatory hM3Dq DREADD during the light period when daily activity of orexin neurons is at its lowest. Orexin-Cre mice were injected with AAV-hSyn-FLEX-hM3Dq-mCherry into the LHA at 8 weeks of age. Wild type mice were also injected with the same AAV vectors as a control. 4 weeks after stereotoxic injection, mice were administered CNO (1.0 mg/kg) by i.p. injection at 12:00 (ZT4), and sacrificed at 13:30 (ZT5.5). We found that i.p. injection of CNO greatly increased c-Fos immunoreactivity in orexin neurons expressing hM3Dq-mCherry (Fig. 2E). Quantitative analyses showed that 55.1 ± 8.5% of orexin-ir neurons expressed c-Fos in orexin-Cre mice injected with CNO (n = 7). This expression level of c-Fos was much higher than that in the mice administered saline (14.7 ± 3.3%) (P < 0.01; Student’s t-test; n = 7) (Fig. 2F). Note that the c-Fos expression rate was increased to 86.7 ± 7.2% if orexin-ir neurons expressing hM3Dq-mCherry were analyzed (n = 7) (Fig. 2F). In wild type mice infected with AAV-hSyn-FLEX-hM3Dq-mCherry, no expression of mCherry was detected. We also confirmed that c-Fos immunoreactivity showed no difference between the wild type mice injected with CNO and saline (data not shown).

3.3. Activation of orexin neurons alters feeding behaviors and metabolism

After the confirmation of selective activation of orexin neurons, we examined the effects of pharmacogenetic activation of orexin neurons on feeding behaviors and metabolism. We employed a CLAMS to simultaneously monitor locomotion, food intake, water intake, and respiratory exchange ratio. The effects of hM3Dq were examined at 12:00 (ZT4) when the activity of orexin neurons is lowest. Saline injection into orexin-Cre mice expressing hM3Dq-mCherry (Tg) was used as the control, and CNO injection into wild-type mice infected with AAV-hSyn-FLEX-hM3Dq-mCherry (WT) was used as an additional control.

Although i.p. injection of saline activated locomotor activity in control mice during the first 30 min after injection (Fig. 3A), stimulation of orexin neurons by i.p. injection of CNO (1.0 mg/kg) induced a significantly greater increase in locomotion compared with controls (Fig. 3B). This increase in locomotion started immediately after injection, and was sustained for about 4 h. One-way ANOVA and Tukey–Kramer post-hoc tests showed that CNO administration into Tg mice significantly increased locomotor activity during the 4 h after injection (P < 0.01; WT, n = 15; Tg, n = 9) (Fig. 3C). The total number of locomotive counts among Tg mice injected with CNO was 4-fold more than in controls (Tg + CNO: 4206 ± 1045 counts, Tg + Saline: 1295 ± 148 counts).
Pharmacogenetic activation also affected food intake. While i.p. injection of saline into WT and Tg mice induced only weak effects on feeding (Fig. 3D), CNO administration into Tg mice rapidly increased food intake (Fig. 3E). This rapid increase in food intake was first recorded within 10 min after injection, and was sustained for approximately 4 h (Fig. 3E). One-way ANOVA and Tukey–Kramer post-hoc tests showed that CNO administration into Tg mice resulted in a significant increase in food intake during the 4 h after injection (P < 0.001; WT, n = 15; Tg, n = 9) (Fig. 3F). The average food intake in orexin neuron-activated mice was 5-fold greater than in saline controls (Tg + CNO; 1.14 ± 0.08 g, Tg + Saline; 0.23 ± 0.04 g).

The effect of pharmacogenetic activation of orexin neurons on water intake was more prominent. Saline injection resulted in almost no change (Fig. 3G), while i.p. injection of CNO into Tg mice induced a strong increase in water intake (Fig. 3H). The increase in water intake also started within the first 10 min after injection, and was sustained for about 4 h, similar to the changes in locomotion and food intake. One-way ANOVA and Tukey–Kramer post-hoc tests showed that CNO administration into Tg mice significantly increased water intake during the 4 h after injection (P < 0.001; WT, n = 15; Tg, n = 9) (Fig. 3I), and the average water intake in orexin neuron-activated mice was 10-fold greater than in saline controls (Tg + CNO; 1.64 ± 0.31 ml, Tg + Saline; 0.16 ± 0.03 ml).

We also found that CNO injection alters metabolic parameters in Tg mice. Injection of saline into Tg mice or CNO injection into WT mice had little effect on the respiratory exchange ratio (RER) (Fig. 3J). In contrast, RER strongly increased after injection of CNO in Tg mice. This change was not so pronounced as the change in locomotion or feeding, but continued even after the change in locomotion had returned to basal levels (Fig. 3K). One-way ANOVA and Tukey–Kramer post-hoc tests showed that CNO administration into hM3Dq-expressing mice significantly increased average RER during the 4 h after injection (P < 0.001; WT, n = 15; Tg, n = 9) (Fig. 3L).

To examine metabolic changes, we also investigated blood glucose levels in transgenic mice. Because pharmacogenetic activation of orexin neurons increases food intake, we removed access to food at 20:00 on the day before the investigation to exclude indirect effects of food digestion on blood glucose levels. We found that i.p. injection of CNO (1.0 mg/kg) increased blood glucose independently from food intake (Fig. 4B) and this effect was maintained for about 6 h. In contrast, injection of saline into Tg mice or CNO into WT mice had little effect on blood glucose levels (Fig. 4A). ANOVA and Tukey’s post-hoc tests showed that CNO administration into hM3Dq-expressing mice resulted in a significant increase in the AUC (area under the curve) during the 6 h after injection (P < 0.001; WT, n = 15; Tg, n = 9) (Fig. 4C).

3.4. Selective ablation of orexin neurons by DTA

To investigate the physiological role of orexin neurons in feeding and metabolism, we employed selective ablation of orexin neurons using DTA. We produced Cre-dependent AAV vectors that selectively induce DTA expression only in cells expressing Cre recombinase (AAV-CMV-FLEX-DTA) (Fig. 5A). DTA catalyzes ADP-ribosylation of eukaryotic elongation factor 2 (Oppenheimer and Bodley, 1981), and causes cell death by inhibiting protein synthesis. We stereotaxically injected AAV-CMV-FLEX-DTA vectors into the LHA of eight-week-old orexin-Cre mice, and sacrificed them 4 weeks after injection.

Immunohistochemistry with anti-orexin-A antibody showed strong ablation of orexin neurons (Fig. 5B). To confirm whether this ablation of orexin neurons was selective, we also performed immunostaining of melanin-concentrating hormone (MCH) neurons as a control. MCH neurons are also localized in the LHA similar to orexin neurons, although their localization is completely segregated. We found that MCH neurons were mostly intact, while orexin neurons were strongly ablated at the same position (Fig. 5B).

We divided orexin neuron-ablated mice into 2 groups since we used 2 different lots of AAV-CMV-FLEX-DTA and there were differences in the resulting extent of ablation. One group was labeled “DTA (70%)” mice as 69.6 ± 2.4% of orexin neurons were ablated in this group, n = 8; the other group was labeled “DTA (83%)” mice as 83.0 ± 1.7% of orexin neurons were ablated in this group, n = 8.

Fig. 5. Selective ablation of orexin neurons by DTA. A: Schematic representation of double-floxed Cre-dependent AAV vector expressing DTA. ITR, inverted terminal repeat; hSyn, human synapsin promoter. B: Coronal brain sections at the level of LHA, prepared from orexin-Cre mice 4 weeks after injection of AAV-CMV-FLEX-DTA. Immunohistochemistry showed that orexin neurons were strongly ablated, while MCH neurons were intact at the same position. C: Quantitative analysis of the number of orexin and D: MCH neurons 4 weeks after the injection of AAV-CMV-FLEX-DTA into orexin-Cre mice. 83.0 ± 1.7% (n = 8) of orexin neurons were ablated, while the number of MCH neurons did not change compared with control mice. The data were analyzed by Student’s t-test.
Quantitative analyses confirmed that the number of MCH neurons in DTA (83%) mice did not change significantly compared with control mice (93.4 ± 3.2%, n = 8) (Fig. 5C and D).

3.5. Feeding behaviors and metabolism in orexin neuron-ablated mice

After the confirmation of selective ablation of orexin neurons, we examined feeding behaviors and metabolism in these orexin neuron-ablated mice using CLAMS. Eight-week-old orexin-Cre mice injected with AAV-CMV-FLEX-DTA (DTA (70%) mice and DTA (83%) mice) or AAV-CMV-FLEX-mCherry vectors (control mice) were analyzed by CLAMS at 12 weeks of age. At least 3 days were allowed for acclimation before sampling the data.

We found that the time course of locomotion in DTA (83%) mice was similar to that in control mice. No strong reciprocal changes between the dark and light periods were observed. Quantitative analysis of total locomotive activity showed a weak decreasing trend in both the light period and dark period, although these differences were not statistically significant (Fig. 6A).

DTA (83%) mice showed a significant decrease in food intake during the light period (one-way ANOVA and Tukey–Kramer post-hoc tests; P < 0.05; n = 8) (Fig. 6B). The total amount of food intake by DTA (83%) mice during the dark period was also lower compared to controls, although the difference was not significant. Note that changes in food intake in DTA (83%) mice during the transition from the light to dark period were slightly reduced compared with control mice.

Most strikingly, water intake was strongly reduced in DTA (83%) mice throughout the entire day (one-way ANOVA and Tukey–Kramer post-hoc tests; P < 0.05; n = 8) (Fig. 6C). This overall decrease in water intake was largely attributed to a decrease during the dark period (one-way ANOVA and Tukey–Kramer post-hoc tests; P < 0.01; n = 8), although water intake during the light period was also less than in control mice. Locomotion, food intake, and water intake in DTA (70%) mice were not significantly changed compared with control mice (Fig. 6A, B and C). Note that these reductions in food and water intake were present even though the average body weight of DTA (83%) mice was significantly larger than control mice (P < 0.01; n = 8; one-way ANOVA followed by Tukey–Kramer tests) (Fig. 7A). Body weight was measured at 12 weeks of age, 4 weeks after injection of AAV vectors. In addition, blood glucose levels of DTA (83%) and DTA (70%) mice were lower than control mice (Fig. 7B).

Fig. 6. Ablation of orexin neurons by DTA diminished food intake and water intake. Orexin-Cre mice were injected with AAV-hSyn-FLEX-mCherry (Control) or AAV-CMV-FLEX-DTA (DTA) in the LHA. After 4 weeks, to allow for gene expression, they were analyzed using a comprehensive laboratory animal monitoring system (CLAMS), which continuously records activity. A: Ambulatory locomotion activity, B: Food intake, and C: Water intake. Measured data are plotted as mean ± SEM (n = 8). The summations of each plot during LP (from ZT 0 to 12), DP (from ZT 12 to 24), and throughout an entire day were analyzed by one-way ANOVA followed by Tukey–Kramer tests. DTA (83%) mice showed decreased food and water intake.
4. Discussion

The orexin system has been implicated in feeding behaviors and metabolism. ICV administration of orexin peptides induces feeding (Sakurai et al., 1998) and drinking behavior (Kunii et al., 1999) and also increases blood glucose via the sympathetic pathway (Yi et al., 2009). Our results using pharmacogenetics fundamentally confirm these roles in feeding and metabolism, but also indicate new insights that are described below. In addition, stable expression of Cre-dependent AAV vectors shows that our new orexin-Cre mice are a valuable tool for manipulating the orexin system in vivo.

4.1. The effects of manipulating orexin neuronal activity by DREADD

In this study we achieved selective activation of orexin neurons using pharmacogenetics. Stereotaxic injection of the AAV vector into the LHA of orexin-Cre mice induced sufficient expression of hM3Dq exclusively in orexin neurons, and neuronal activation by CNO was confirmed by electrophysiology and c-Fos immunohistochemistry. Activation of orexin neurons induced concurrent increases in locomotion, food intake, and water intake, and affected metabolic factors such as respiratory exchange ratio and blood glucose level. These findings enhance our understanding of the integrative function of orexin neurons on feeding and metabolism. As far as we know, this is the first study to comprehensively investigate the effects of manipulating orexin neuronal activity on feeding and metabolism.

The induction of elevated food and water intake was sustained for at least 4 h. It has been reported that activation of food and water intake by ICV administration of orexin peptides returned to baseline within 2 h (Kunii et al., 1999). Because the CNO (1.0 mg/kg; i.p.) used in this study is supposed to be cleared from blood plasma within 2 h (Guettier et al., 2009), it is possible that the longer-lasting effects of pharmacogenetic activation on feeding behaviors is derived from the activity of co-factors released along with orexins. However, other alternative explanations should be carefully considered. It was reported that activation of forebrain principal neurons by hM3Dq can induce very long effects on locomotion up to 9 h (Alexander et al., 2009). It was also reported that carbachol-induced gamma rhythm in hippocampal slices persists even after the removal of carbachol from the bath (Fisahn et al., 1998). Therefore, transient activation of muscarinic receptors (and hM3Dq) can induce persistent responses in some neurons.

The effect on blood glucose might be derived from activation of sympathetic nerves. Orexin can influence liver function via the sympathetic pathway (van Den Top et al., 2003) and it has also been reported that the stimulatory effect on blood glucose by ICV administration of orexin-A was prevented by hepatic sympathetic denervation (Yi et al., 2009). Therefore, it is also possible that the sustained effects on blood glucose and RER by CNO result from the involvement of indirect signal transduction downstream of orexin neurons.

4.2. Sustained in vivo manipulation of metabolism by DREADD

Recently, a growing number of optogenetic studies have revealed the physiological functions of orexin neurons in the regulation of sleep and arousal (Adamantidis et al., 2007; Tsunematsu et al., 2011; Carter et al., 2012). However, it is difficult to alter sustained neuronal activity over a few hours using optogenetics due to inactivation of photo-activated channels or pumps. For example, our group found that optogenetic inhibition of orexin neurons by halorhodopsin was only sustained for a few minutes (Tsunematsu et al., 2011). Arch or ArchT are more stable than halorhodopsin, but they are still not able to inhibit neuronal activity for multiple hours. In addition, optogenetic activation depolarizes neurons in an extremely synchronized manner, which is not likely to happen under physiological conditions. Furthermore, channelrhodopsin2 is much more permeable to H+ than Na+, and its activation can induce intracellular acidification and affect cellular signaling (Beppu et al., 2014). Given these limitations of optogenetics, DREADD is a valuable alternative tool for manipulating endogenous signaling, although its time resolution is not as high.

In this study, pharmacogenetic activation of orexin neurons could alter RER and blood glucose for as long as 6 h. It was reported that cholecystokinin (CCK) activates orexin neurons through the cholecystokinin A receptor (Tsujino et al., 2005). CCK4 couples with the Gq subclass of G-proteins, and subsequently depolarizes membrane potential via activation of non-selective cation channels, likely TRP channels in orexin neurons. These pathways might be involved in hM3Dq-mediated activation of orexin neurons since hM3Dq is reported to activate the endogenous Gq pathway. The longer-term effects and the facility of pharmacogenetics are suitable for various behavioral testing and physiological experiments (Ray et al., 2011; Krashes et al., 2013). Recently it was shown that manipulation of orexin neuronal activity by DREADD can affect states of sleep/wakefulness (Saakii et al., 2011). Our study extends the application of DREADD to additional behaviors including feeding and metabolism. In addition, this pharmacogenetic technique does not require optic fibers for stimulation, so it is suitable for usage in closed cages for monitoring metabolic factors such as O2 consumption or CO2 emission.

Fig. 7. Ablation of orexin neurons affects blood glucose and body weight. Orexin-Cre mice were injected with AAV-hSyn-FLEX-mCherry (Control) or AAV-CMV-FLEX-DTA (DTA) vectors in the LHA. After 4 weeks they were measured. A: Body weight and B: blood glucose. Measured data are plotted as mean ± SEM (n = 8). The data were analyzed by one-way ANOVA followed by Tukey-Kramer tests.

---

\( \text{Body weight (g)} \)

\( \text{Blood glucose (mg/dL)} \)

\( \text{Control} \quad \text{DTA (70%)} \quad \text{DTA (83%)} \)

A: Body weight and B: blood glucose. Measured data are plotted as mean ± SEM (n = 8). The data were analyzed by one-way ANOVA followed by Tukey-Kramer tests.
4.3. Robust regulation of feeding behaviors by orexin neurons

Previous studies have shown that ablation of orexin neurons induces severe fragmentation of sleep/wakefulness cycles and late-onset obesity (Hara et al., 2001). Therefore, it is surprising that a 70% ablation of orexin neurons showed almost no change in these parameters. This finding implies that only a small percentage of orexin neurons are required to maintain their function in sleep-wakefulness, feeding behaviors, and metabolic regulation. It is known that more than 70% of dopaminergic neurons are lost in the substantia nigra pars compacta before the onset of Parkinson’s disease (Lang and Lozano, 1998). In addition, postmortem studies of narcoleptic subjects indicated an 80—100% reduction in the number of orexin neurons, determined by in situ hybridization (Peyron et al., 2000). These findings suggest the robust regulation of feeding behavior and metabolism by orexin neurons.

Conversely, pharmacogenetic activation of orexin neurons showed strong effects, although the expression rate of hM3Dq was lower than that of DTA. It has been reported that orexin neurons express orexin receptors and can be activated by orexin peptides (Yamanaka et al., 2010). This positive feedback might explain the expression orexin receptors and can be activated by orexin peptides (et al., 2000). These

in situ

that more than 70% of dopaminergic neurons are lost in the sub-

stability, feeding behaviors, and metabolic regulation. It is known

orexin neurons are required to maintain their function in wake-

fi

70% ablation of orexin neurons showed almost no change in these

results indicate the robust and concurrent regulation of feeding behaviors and metabolism by orexin neurons.

Acknowledgments

This study was supported by a Grant-in-Aid for Scientific Research (B) (23300142) and a Grant-in-Aid for Scientific Research on Innovative Area “Mesoscopic Neurocircuity” (23115103) (A.Y.), and by a Grant-in-Aid for Young Scientists (B) (20860157) and a Grant-in-Aid for Scientific Research on Innovative Area “The Evolutionary Origin and Neural Basis of the Empathetic Systems” (26118507) (A.I.), and by a Grant-in-Aid for Scientific Research (B) (24300129) and the World Premier International Research Center Initiative (WPI) from the Ministry of Education, Culture, Sports, Science, and Technology (M.L.). We thank C. Saito and K. Nishimura for technical assistance.

References

Abrahamson, E.E., Leak, R.K., Moore, R.Y., 2001. The suprachiasmatic nucleus projects to posterior hypothalamic arousal systems. Neuroreport 12, 435—440.

Adamantidis, A.R., Zhang, F., Aravanis, A.M., Deisseroth, K., De Lecea, L., 2007. Neural oscillations at 40 Hz in the hippocampus in vitro. Nature 394, 186—189.

Guettier, J.M., Gautam, D., Scarselli, M., Ruiz De Azua, I., Li, J.H., Rosemond, E., Ma, X., Gonzalez, F.J., Armbruster, B.N., Lu, H., Roth, B.L., Wess, J., 2009. A chemical-genetic approach to study G protein regulation of beta cell function in vivo. Proc. Natl. Acad. Sci. U. S. A. 106, 19197—19202.

Hara, J., Beuckmann, C.T., Nambu, T., Willie, J.T., Chemelli, R.M., Saper, C.B., Scammell, T.E., 2001. Fos expression in orexin neurons varies with behavioral state. J. Neuroscience 21, 1656—1662.

Fiset, P., Pike, F.G., Buhr, E.D., et al., 1998. Cholinergic induction of network oscillations at 40 Hz in the hippocampus in vivo. Nature 394, 186—189.

Krashes, M.J., Shah, B.P., Koda, S., Chen, J.F., 2011. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J. Neuroscience 31, 10087—10107.

Singleton, A.C., Hanyaloglu, A., Taneja, K., Javitt, D.C., 2011. Determination of the key to create a family of G protein-coupled receptors potently activating the Gq pathway. Proc. Natl. Acad. Sci. U. S. A. 108, 1662—1667.

Dymecki, S.M., 2011. Impaired respiratory and body temperature control upon neuronal systems. J. Neurosci. 18, 9996—10008.

Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., Takahashi, S., Kiyama, H., Inutsuka, A., Yamamoto, M., 2002. The human prepro-orexin gene regulatory region that activates gene expression in the human prepro-orexin gene regulatory region that activates gene expression in the lateral region and represses it in the medial regions of the hypothalamus. J. Biol. Chem. 277, 16985—16992.

Nambu, T., Sakurai, T., Mizukawa, K., Hosoya, Y., Yanagisawa, M., Goto, K., 1999. Orexins/hypocretins regulate drinking behaviour. Brain Res. 842, 256—251.

Lang, A.E., Lozano, A.M., 1998. Parkinson’s disease. First of two parts. N. Engl. J. Med. 339, 1044—1053.

Nishino, S., Ripley, B., Overeem, S., Lammers, G.J., Mignot, E., 2000. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39—40.

Oppenheimer, N.J., Boldar, I.W., 1981. Diphtheria toxin. Site and conformation of ADP-ribosylation of diphthamide in elongation factor 2. J. Biol. Chem. 256, 8579—8581.

Peyron, C., Faraco, J., Rogers, W., Ripley, B., Overeem, S., Charness, Y., Neves-Silva, R., Aldrich, M., Reynolds, D., Albin, R., Li, L., Hungs, M., Pedrazzoli, M., Padigaru, M., Kucherlapati, R., Fan, J., Maki, R., Lammers, G.J., Bouras, C., Kucherlapati, R., Nishino, S., Mignot, E., 2000. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991—997.

Peyron, C., Tighe, D.K., Van Den Pol, A.N., De Lecea, L., Heller, H.C., Sutcliffe, J.G., Kilduff, T.S., 1998. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9966—10015.

Ray, R.S., Corcoran, A.E., Brust, R.D., Kim, J.C., Richardson, G.B., Nattie, E., Dymecki, S.M., 2011. Impaired respiratory and body temperature control upon acute serotonin receptor inhibition. Science 333, 637—642.

Sakurai, T., 2007. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat. Rev. Neurosci. 8, 171—181.

Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., Williams, S.C., Richardson, J.A., Kozlowski, G.P., Wilson, S., Arch, J.R., Buckmaster, R.E., Haynes, A.C., Carr, S.A., Annan, R.S., McNulty, D.E., Liu, W.S., Terret, J.A., Elshourbagy, N.A., Bergsma, D.J., Yanagisawa, M., 1998. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 1 page following 6969.
Sakurai, T., Moriguchi, T., Furuya, K., Kajiwara, N., Nakamura, T., Yanagisawa, M.,
Goto, K., 1999. Structure and function of human prepro-orexin gene. J. Biol.
Chem. 274, 17771–17776.
Sasaki, K., Suzuki, M., Mieda, M., Tsujino, N., Roth, B., Sakurai, T., 2011. Pharmaco-
genetic modulation of orexin neurons alters sleep/wakefulness states in mice.
PLoS One 6, e20360.
Szyniczak, A.L., Workman, C.J., Wang, Y., Vignali, K.M., Diliegloiu, S., Vanin, E.F.,
Vignali, D.A., 2004. Correction of multi-gene deficiency in vivo using a single
'self-cleaving' 2A peptide-based retroviral vector. Nat. Biotechnol. 22, 589–594.
Thannickal, T.C., Moore, R.Y., Niemhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M.,
Cornford, M., Siegel, J.M., 2000. Reduced number of hypocretin neurons in
human narcolepsy. Neuron 27, 469–474.
Tsujino, N., Yamanaka, A., Ichiki, K., Muraki, Y., Kilduff, T.S., Yagami, K., Takahashi, S.,
Goto, K., Sakurai, T., 2005. Cholecystokinin activates orexin/hypocretin neurons
through the cholecystokinin A receptor. J. Neurosci. 25, 7459–7469.
Tsunematsu, T., Kilduff, T.S., Boyden, E.S., Takahashi, S., Tominaga, M., Yamanaka, A.,
2011. Acute optogenetic silencing of orexin/hypocretin neurons induces slow-
wave sleep in mice. J. Neurosci. 31, 10529–10539.
Tupone, D., Madden, C.J., Cano, G., Morrisson, S.F., 2011. An orexnergic projection
from perifornical hypothalamus to raphe pallidus increases rat brown adipose
tissue thermogenesis. J. Neurosci. 31, 15944–15955.
Van Den Top, M., Nolan, M.F., Lee, K., Richardson, P.J., Buijs, R.M., Davies, C.H.,
Spanswick, D., 2003. Orexins induce increased excitability and synchronisation
of rat sympathetic preganglionic neurones. J. Physiol. 549, 809–821.
Yamanaka, A., Sakurai, T., Katsumoto, T., Yanagisawa, M., Goto, K., 1999. Chronic
intracerebroventricular administration of orexin-A to rats increases food
intake in daytime, but has no effect on body weight. Brain Res. 849, 248–252.
Yamanaka, A., Tabuchi, S., Tsunematsu, T., Fukazawa, Y., Tominaga, M., 2010. Orexin
directly excites orexin neurons through orexin 2 receptor. J. Neurosci. 30,
12642–12652.
Yi, C.X., Serlie, M.J., Ackermans, M.T., Foppen, E., Buijs, R.M., Sauerwein, H.P.,
Flies, E., Kalsbeek, A., 2009. A major role for perifornical orexin neurons in the
control of glucose metabolism in rats. Diabetes 58, 1998–2005.